Covid-19 roundup: NRx's med gets axed from NIH trial over futility; A new drug for the pandemic enters the clinic
There were more deaths in the treatment group than placebo cohort in an NIH study of NRx Pharmaceuticals’ already-rejected Covid-19 drug, and the data safety board recommended stopping the trial.
The board said the study of Zyesami or aviptadil, the last remaining investigational med in the NIH’s ACTIV-3b trial of critical Covid-19 patients, should end because of futility. The primary goal of 90 day 6-category ordinal score was “not supportive” and the mortality secondary endpoint was also not good enough to push the drug further.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
